Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
5/9/2026, 12:00:00 AM
HS-20093 granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma on 2026-05-09; estimated 5% impact from accelerated approval path.
Korean Translation
2026-05-09, HS-20093의 식도 편평세포암 혁신 치료제 지정됨. 승인 절차 가속화로 약 5%의 주가 영향이 예상됨.
Related Recent Events
JD Health International Inc (6618) · Earnings Release
Low importance estimated as no market reaction has occurred yet; Q2 2026 earnings report scheduled.
8/12/2026, 12:00:00 AM
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date on June 16, 2026, for the final dividend of RMB 1.43 per 10 shares, scheduled to be paid on July 13, 2026. Low importance estimated as the dividend amount is within historical norms, scheduled.
6/16/2026, 12:00:00 AM
Grand Pharmaceutical Group Ltd (512) · Other
Ex-dividend date (2026-06-12) for the proposed 2025 final dividend of HK$0.169 per share is scheduled.
6/12/2026, 12:00:00 AM
Veracyte Inc (VCYT) · Other
Annual Meeting of Stockholders on 2026-06-10, with proposals including the election of directors and an expansion of the 2023 Equity Incentive Plan scheduled.
6/10/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Pacific Biosciences of California Inc (PACB) · Other
The 2026 Annual Meeting of Stockholders is scheduled for June 3, 2026, including a proposal to increase the number of shares reserved for the 2020 Equity Incentive Plan by 16,000,000. A low impact is estimated due to potential share dilution, scheduled.
6/3/2026, 12:00:00 AM